INmune Bio, Inc.(INMB)Earnings, Financials & Key Ratios
INMB•NASDAQ
$1.52
$40M mkt cap·Price updated May 6, 2026
AboutINmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Show more
- Revenue$14K-91.0%
- EBITDA-$42M
- Net Income-$42M-40.2%
- EPS (Diluted)-2.11-26.3%
- Gross Margin100%
- EBITDA Margin-300585.71%
- Operating Margin-304535.71%-1487.1%
- Net Margin-300585.71%-1452.6%
- ROE-119.83%-96.2%
- ROIC-263.32%-112.4%
- Debt/Equity0.01-95.6%
INMB Key Insights
INmune Bio, Inc. (INMB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 10.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
INMB Price & Volume
INmune Bio, Inc. (INMB) stock price & volume — 10-year historical chart
Loading chart...
INMB Growth Metrics
INmune Bio, Inc. (INMB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-57.39%
TTM19.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM2.29%
Return on Capital
10 Years-178.77%
5 Years-57.65%
3 Years-68.62%
Last Year-120.31%
INMB Peer Comparison
INmune Bio, Inc. (INMB) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare INMB vs Peers
INmune Bio, Inc. (INMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INMB Income Statement
INmune Bio, Inc. (INMB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 11K | 181K | 374K | 155K | 14K | 50K |
| Revenue Growth % | - | - | - | - | - | 1545.45% | 106.63% | -58.56% | -90.97% | 19.05% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 11K▲ 0% | 181K▲ 1545.5% | 374K▲ 106.6% | 155K▼ 58.6% | 14K▼ 91.0% | 22K▲ 0% |
| Gross Margin % | - | - | - | - | 100% | 100% | 100% | 100% | 100% | 44% |
| Gross Profit Growth % | - | - | - | - | - | 1545.45% | 106.63% | -58.56% | -90.97% | - |
| Operating Expenses | 227.49K | 981.48K | 12.44M | 7.76M | 12.24M | 29.33M | 26.32M | 29.9M | 42.65M | 51.4M |
| OpEx % of Revenue | - | - | - | - | 111263.64% | 16206.63% | 7038.77% | 19287.74% | 304635.71% | - |
| Selling, General & Admin | 126K | 546.12K | 9.09M | 4.47M | 6.32M | 8.79M | 9.26M | 9.62M | 9.48M | 9.2M |
| SG&A % of Revenue | - | - | - | - | 57463.64% | 4856.91% | 2475.4% | 6208.39% | 67735.71% | - |
| Research & Development | 101.5K | 435.36K | 1.1M | 3.28M | 5.92M | 20.54M | 17.07M | 20.27M | 33.17M | 25.68M |
| R&D % of Revenue | - | - | - | - | 53790.91% | 11349.72% | 4563.37% | 13079.35% | 236900% | - |
| Other Operating Expenses | 0 | -6 | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 1000K |
| Operating Income | -227K▲ 0% | -981K▼ 332.2% | -12.44M▼ 1168.1% | -7.76M▲ 37.7% | -12.23M▼ 57.7% | -29.15M▼ 138.4% | -25.95M▲ 11.0% | -29.74M▼ 14.6% | -42.63M▼ 43.4% | -51.38M▲ 0% |
| Operating Margin % | - | - | - | - | -111163.64% | -16106.63% | -6938.77% | -19187.74% | -304535.71% | -102752% |
| Operating Income Growth % | -364.52% | -332.16% | -1168.09% | 37.65% | -57.66% | -138.41% | 10.98% | -14.6% | -43.35% | - |
| EBITDA | 491 | 480 | 0 | -7.68M | 0 | 0 | 0 | 0 | -42.08M | -34.59M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -300585.71% | -69170% |
| EBITDA Growth % | -99.67% | -2.24% | -100% | - | 100% | - | - | - | - | -9.83% |
| D&A (Non-Cash Add-back) | 227.49K | 981.48K | 12.44M | 0 | 12.23M | 29.15M | 25.95M | 29.74M | 553K | 28K |
| EBIT | -277K | -831K | -12.44M | -7.68M | -12.23M | -29.15M | -25.95M | -29.74M | -42.63M | -33.65M |
| Net Interest Income | 0 | 0 | 0 | 77.69K | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 77.69K | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -50K | 149.99K | 0 | 77.69K | 129K | -1.19M | -1.35M | -267K | 553K | 1.49M |
| Pretax Income | -277K▲ 0% | -831K▼ 200.0% | -12.44M▼ 1397.0% | -7.68M▲ 38.3% | -12.1M▼ 57.6% | -30.34M▼ 150.8% | -27.3M▲ 10.0% | -30.01M▼ 9.9% | -42.08M▼ 40.2% | -49.89M▲ 0% |
| Pretax Margin % | - | - | - | - | -109990.91% | -16762.43% | -7299.2% | -19360% | -300585.71% | -99774% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -277K▲ 0% | -831K▼ 200.0% | -12.44M▼ 1397.0% | -7.68M▲ 38.3% | -12.1M▼ 57.6% | -30.34M▼ 150.8% | -27.3M▲ 10.0% | -30.01M▼ 9.9% | -42.08M▼ 40.2% | -49.89M▲ 0% |
| Net Margin % | - | - | - | - | -109990.91% | -16762.43% | -7299.2% | -19360% | -300585.71% | -99774% |
| Net Income Growth % | -466.83% | -200% | -1396.99% | 38.28% | -57.57% | -150.76% | 10.02% | -9.92% | -40.24% | -20.87% |
| Net Income (Continuing) | -277K | -831K | -12.44M | -7.68M | -12.1M | -30.34M | -27.3M | -30.01M | -42.08M | -49.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05▲ 0% | -0.07▼ 36.7% | -1.11▼ 1398.0% | -0.89▲ 19.8% | -1.01▼ 13.5% | -1.88▼ 86.1% | -1.52▲ 19.1% | -1.67▼ 9.9% | -2.11▼ 26.3% | -1.88▲ 0% |
| EPS Growth % | - | -36.72% | -1397.98% | 19.82% | -13.48% | -86.14% | 19.15% | -9.87% | -26.35% | 2.29% |
| EPS (Basic) | -0.05 | -0.07 | -1.11 | -0.89 | -1.01 | -1.88 | -1.52 | -1.67 | -2.11 | - |
| Diluted Shares Outstanding | 5.11M | 11.22M | 11.22M | 10.27M | 11.99M | 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
| Basic Shares Outstanding | 5.11M | 11.22M | 11.22M | 10.27M | 11.99M | 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INMB Balance Sheet
INmune Bio, Inc. (INMB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 451.61K | 1.9M | 849.34K | 7.76M | 23.99M | 82.61M | 64.67M | 39.94M | 22.66M | 30.67M |
| Cash & Short-Term Investments | 141.66K | 1.37M | 186.2K | 7M | 21.97M | 74.81M | 52.15M | 35.85M | 20.92M | 27.73M |
| Cash Only | 141.66K | 1.37M | 186.2K | 7M | 21.97M | 74.81M | 52.15M | 35.85M | 20.92M | 27.73M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 327.61K | 647.59K | 645.36K | 0 | 5.5M | 8.46M | 2.44M | 1.41M | 2.46M |
| Days Sales Outstanding | - | - | - | - | - | 11.1K | 8.26K | 5.75K | 36.73K | 13.59K |
| Inventory | 0 | 0 | 0 | -769.13M | 0 | -5.5M | 34K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 306.95K | 0 | 0 | 769.13M | 1.8M | 5.5M | -34K | 0 | 331K | 472K |
| Total Non-Current Assets | 0 | 16.51M | 16.51M | 16.71M | 16.67M | 17.34M | 17.12M | 17.06M | 16.9M | 2.69M |
| Property, Plant & Equipment | 0 | 0 | 0 | 191.54K | 156K | 726K | 507K | 414K | 307K | 1.06M |
| Fixed Asset Turnover | - | - | - | - | 0.07x | 0.25x | 0.74x | 0.37x | 0.05x | 0.07x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 99K | 99K | 131K | 79K | 2.32M |
| Total Assets | 451.61K▲ 0% | 18.41M▲ 3977.3% | 17.36M▼ 5.7% | 24.47M▲ 40.9% | 40.66M▲ 66.1% | 99.94M▲ 145.8% | 81.8M▼ 18.2% | 57M▼ 30.3% | 39.56M▼ 30.6% | 33.36M▲ 0% |
| Asset Turnover | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | 3700.77% | 3977.32% | -5.7% | 40.93% | 66.14% | 145.83% | -18.16% | -30.31% | -30.59% | -114.84% |
| Total Current Liabilities | 600.81K | 309.72K | 823.77K | 700.38K | 1.78M | 4.36M | 10.92M | 18.46M | 7.22M | 7.36M |
| Accounts Payable | 220.81K | 136.4K | 553.22K | 401.99K | 1.52M | 3.8M | 5.21M | 7.9M | 6.56M | 6.9M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | 93.27K |
| Short-Term Debt | 350K | 0 | 0 | 0 | 0 | 72K | 5M | 9.92M | 0 | 457K |
| Deferred Revenue (Current) | 0 | 0 | 0 | -298.39K | 0 | 474K | 616K | 0 | 0 | 0 |
| Other Current Liabilities | 30K | 0 | 0 | 298.39K | 190K | -62K | 9K | 524K | 517K | -457K |
| Current Ratio | 0.75x | 6.13x | 1.03x | 11.09x | 13.51x | 18.95x | 5.92x | 2.16x | 3.14x | 3.14x |
| Quick Ratio | 0.75x | 6.13x | 1.03x | 1109.25x | 13.51x | 20.21x | 5.92x | 2.16x | 3.14x | 3.14x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -79.69K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 160.16K | 126K | 15.36M | 10.77M | 397K | 244K | 623K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 14.46M | 9.7M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 160.16K | 126K | 704K | 526K | 397K | 244K | 1.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 199K | 550K | 0 | 0 | 0 |
| Total Liabilities | 600.81K | 309.72K | 823.77K | 860.54K | 1.9M | 19.72M | 21.69M | 18.86M | 7.46M | 7.98M |
| Total Debt | 350K | 0 | 0 | 168.45K | 160K | 15.23M | 15.31M | 10.44M | 384K | 1.08M |
| Net Debt | 208.34K | -1.37M | -186.2K | -6.83M | -21.81M | -59.58M | -36.84M | -25.41M | -20.54M | -26.65M |
| Debt / Equity | - | - | - | 0.01x | 0.00x | 0.19x | 0.25x | 0.27x | 0.01x | 0.01x |
| Debt / EBITDA | 712.83x | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | 424.32x | -2855.65x | - | - | - | - | - | - | - | 0.77x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -149.2K▲ 0% | 18.1M▲ 12233.6% | 16.54M▼ 8.6% | 23.61M▲ 42.7% | 38.75M▲ 64.1% | 80.22M▲ 107.0% | 60.1M▼ 25.1% | 38.14M▼ 36.5% | 32.1M▼ 15.8% | 25.38M▲ 0% |
| Equity Growth % | -690.77% | 12233.64% | -8.64% | 42.75% | 64.14% | 107.01% | -25.08% | -36.55% | -15.84% | -70.13% |
| Book Value per Share | -0.03 | 1.61 | 1.47 | 2.30 | 3.23 | 4.97 | 3.35 | 2.12 | 1.61 | 0.95 |
| Total Shareholders' Equity | -149.2K | 18.1M | 16.54M | 23.61M | 38.75M | 80.22M | 60.1M | 38.14M | 32.1M | 25.38M |
| Common Stock | 5.07K | 8.32K | 8.72K | 10.77K | 13K | 18K | 18K | 817K | 22K | 27K |
| Retained Earnings | -326.36K | -1.16M | -13.6M | -21.28M | -33.38M | -63.72M | -91.01M | -121.02M | -163.1M | -203.77M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 47.16K | 32.04K | 6.53K | -8.52K | 11K | 1K | -699K | -799K | -575K | -764K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INMB Cash Flow Statement
INmune Bio, Inc. (INMB) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -317.38K | -761.83K | -2.06M | -5.38M | -8.94M | -28.5M | -22.69M | -11.98M | -33.36M | -33.36M |
| Operating CF Margin % | - | - | - | - | -81305.87% | -15748.07% | -6065.78% | -7729.03% | -238292.86% | - |
| Operating CF Growth % | -1651.73% | -140.04% | -170.27% | -161.52% | -66.09% | -218.71% | 20.41% | 47.19% | -178.47% | -186.47% |
| Net Income | -277.49K | -831.49K | -12.44M | -7.68M | -12.1M | -30.34M | -27.3M | -30.01M | -42.08M | -49.89M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 199.56K | 10M | 4.1M | 0 | 4.8M | 7.15M | 7.37M | 7.61M | 8.35M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 50K | -150K | 9.81M | -1.54M | 3.11M | 126K | 328K | 224K | 79K | 15.92M |
| Working Capital Changes | -89.89K | 20.1K | 379.67K | -260.88K | 43.51K | -3.09M | -2.86M | 10.44M | 1.04M | -5.04M |
| Change in Receivables | -260.49K | -67.12K | -319.98K | 2.22K | -1.15M | -3.71M | -2.96M | 6.02M | 1.03M | -1.04M |
| Change in Inventory | 0 | 0 | 0 | -2.22K | 0 | 3.71M | 2.96M | 0 | 0 | 0 |
| Change in Payables | 220.06K | 238.91K | 514.05K | -131.68K | 1.08M | 2.26M | 1.4M | 2.72M | -1.37M | -3.12M |
| Cash from Investing | 0 | -100K | 0 | 0 | 0 | -15M | 0 | 0 | 0 | -899K |
| Capital Expenditures | 0 | -100K | 0 | 0 | 0 | -15M | 0 | 0 | 0 | -899K |
| CapEx % of Revenue | - | - | - | - | 0.04% | 8287.29% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 450K | 2.06M | 900K | 12.21M | 23.9M | 96.36M | 729K | -4.22M | 18.21M | 25.47M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 14.95M | 0 | -5M | -10M | -2.5M |
| Equity Issued (Net) | 450K | 1000K | 900K | 1000K | 1000K | 1000K | 699K | 775K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -1.01M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 1.15M | 30K | 0 | 422K | 423K |
| Net Change in Cash | 129.78K▲ 0% | 1.23M▲ 847.0% | -1.18M▼ 196.4% | 6.81M▲ 674.9% | 14.97M▲ 119.9% | 52.84M▲ 253.0% | -22.66M▼ 142.9% | -16.3M▲ 28.0% | -14.93M▲ 8.5% | -5.82M▲ 0% |
| Free Cash Flow | -317.38K▲ 0% | -861.83K▼ 171.5% | -2.06M▼ 138.9% | -5.38M▼ 161.5% | -8.94M▼ 66.1% | -43.5M▼ 386.4% | -22.69M▲ 47.9% | -11.98M▲ 47.2% | -33.36M▼ 178.5% | -31.55M▲ 0% |
| FCF Margin % | - | - | - | - | -81305.91% | -24035.36% | -6065.78% | -7729.03% | -238292.86% | -63100% |
| FCF Growth % | -1651.73% | -171.55% | -138.91% | -161.52% | -66.1% | -386.42% | 47.85% | 47.19% | -178.47% | -22.53% |
| FCF per Share | -0.06 | -0.08 | -0.18 | -0.52 | -0.75 | -2.70 | -1.27 | -0.67 | -1.67 | -1.67 |
| FCF Conversion (FCF/Net Income) | 1.15x | 0.92x | 0.17x | 0.70x | 0.74x | 0.94x | 0.83x | 0.40x | 0.79x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.03M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INMB Key Ratios
INmune Bio, Inc. (INMB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -9.26% | -71.82% | -38.25% | -38.8% | -51% | -38.91% | -61.09% | -119.83% | -172% |
| Return on Invested Capital (ROIC) | -1199.45% | -8.76% | -56.4% | -35.11% | -54.38% | -116.31% | -88.65% | -123.96% | -263.32% | -263.32% |
| Gross Margin | - | - | - | - | 100% | 100% | 100% | 100% | 100% | 44% |
| Net Margin | - | - | - | - | -109990.91% | -16762.43% | -7299.2% | -19360% | -300585.71% | -99774% |
| Debt / Equity | - | - | - | 0.01x | 0.00x | 0.19x | 0.25x | 0.27x | 0.01x | 0.01x |
| FCF Conversion | 1.15x | 0.92x | 0.17x | 0.70x | 0.74x | 0.94x | 0.83x | 0.40x | 0.79x | 0.63x |
| Revenue Growth | - | - | - | - | - | 1545.45% | 106.63% | -58.56% | -90.97% | 19.05% |
INMB Frequently Asked Questions
INmune Bio, Inc. (INMB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
INmune Bio, Inc. (INMB) reported $0.1M in revenue for fiscal year 2024.
INmune Bio, Inc. (INMB) saw revenue decline by 91.0% over the past year.
INmune Bio, Inc. (INMB) reported a net loss of $49.9M for fiscal year 2024.
Dividend & Returns
INmune Bio, Inc. (INMB) has a return on equity (ROE) of -119.8%. Negative ROE indicates the company is unprofitable.
INmune Bio, Inc. (INMB) had negative free cash flow of $31.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More INMB
INmune Bio, Inc. (INMB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates